Immune-checkpoint Drugs in Oncology: Analytical Tool

Wednesday, November 7, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Nov. 6, 2018 /PRNewswire/ -- Cancer cells sometimes find ways to avoid being attacked by the immune system. But the

event of immune-checkpoint drugs such as nivolumab (Opdivo) and pembrolizumab (Keytruda) have dramatically changed the possibility to harness the power of the immune system in fighting cancer not only as a monotherapy but, maybe more importantly, also
as a combination therapy.Download the full report: Immune-checkpoint Drugs in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in immune-oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your immune-checkpoint drug intelligence.Your Immune-checkpoint Drugs in Oncology: Analytical Tool is based on two decades of proven methodology in serving clients with interest in:* Target Scouting* Early & Late Stage Pipeline Analysis* Biomarker/Companion Diagnostic Analysis (featured below)* Deal & Alliance Analysis* Conference surveillance of world leading cancer meetings (featured below)* Combination Therapy Analysis (featured below)* Clinical Trial Results Analysis* Indication Selection & Expansion Analysis* First-in-Class Analysis* Drug Repositioning* Pipeline Analysis by Targeted Pathways* Instantly generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts)Analytical Tools transform your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.Your Immune-checkpoint Drugs in Oncology: Analytical Tool covers more than 223 companies plus partners who are today developing 501 immune-checkpoint drugs where of 473 are in active development in cancer across 108 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.Let our expertise work for youWith a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.Your key to access development at the world-leading cancer meetingsThe Immune-checkpoint Drugs in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CIMT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.Run combination therapy analysis like no otherThe Immune-checkpoint Drugs in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.Unparalleled biomarker surveillanceWe also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.Support and inspiration at your finger-tipsYou also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.A tool to grow with and keep you informedUnlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.System Requirements- Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))- Internet accessDownload the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +1 (718) 213 4904 Website:

Cision View original content:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store